Zobrazeno 1 - 10
of 47 833
pro vyhledávání: ''
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 38:122-131
Background: Gastric cancer (GC) is a common tumor found worldwide, and cisplatin is the first-line agent for the treatment of GC. However, the resistance to cisplatin is an obstacle. Here, we aim to explore the biological mechanism of long noncoding
Autor:
Lars Bullinger, Jörg Westermann
Publikováno v:
Seminars in Cancer Biology. 84:153-169
Myeloid malignancies have always been at the forefront of an improved understanding of the molecular pathogenesis of cancer. In accordance, over the last years, basic research focusing on the aberrations underlying malignant transformation of myeloid
Autor:
Prakash Priyadarshi Praharaj, Debasna P. Panigrahi, Bishnu Prasad Behera, Kewal Kumar Mahapatra, Shankargouda Patil, Amruta Singh, Rohan Dhiman, Srimanta Patra, Soumya Ranjan Mishra, Chandra Sekhar Bhol, Sujit K. Bhutia, Samir Kumar Patra
Publikováno v:
Seminars in Cancer Biology. 83:399-412
Tumour-promoting inflammation is a critical hallmark in cancer development, and inflammasomes are well-known regulators of inflammatory processes within the tumour microenvironment. Different inflammasome components along with the adaptor, apoptosis-
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 37:233-245
Background: The occurrence of cisplatin (DDP) resistance in oral squamous cell carcinoma (OSCC) is a major challenge for OSCC treatment. Circular RNAs (circRNAs) have been associated with the devel...
Autor:
Thorsten Lehr, Hannah Britz, Clinton F. Stewart, Daniel Moj, Walter E. Haefeli, Gerlinde Egerer, Jürgen Burhenne
This study aimed at recommending pediatric dosages of the histone deacetylase (HDAC) inhibitor vorinostat and potentially more effective adult dosing regimens than the approved standard dosing regimen of 400 mg/day, using a comprehensive physiologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b42701510c1983fe755fd57a7800a87
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
François Pinquie, Alain Morel, Benjamin Morvan, Jérémy Sandrini, Olivier Molinier, Alexis B. Cortot, Camille Guguen, Louise-Marie Chevalier
Publikováno v:
Clinical Lung Cancer. 23:e131-e134
Clinical Practice Points • What is already known about this subject? • Resistance mechanisms to osimertinib in T790M positive NSCLC patients are multiple and heterogeneous, combining de novo EGFR alterations (C797S mutation), EGFR-independent mec
Autor:
Daniel M. Berney, Jonathan Shamash, T. Oliver, Anju Sahdev, S. J. Harland, Andrew Gogbashian, Constantine Alifrangis, Gordon J. S. Rustin, Samita Agarwal, Marina Milic, Sarah Duncan, Sara Stoneham, Shafi Chowdhury, Anand Sharma, Michelle Lockley, Peter Wilson
Publikováno v:
European Journal of Cancer. 164:105-113
Background Radiotherapy and cisplatin-based combination chemotherapy are accepted standard-of-care treatments for metastatic seminoma with excellent survival outcomes but with established short- and long-term morbidity. Carboplatin monotherapy may be
Autor:
Ming Li, Quan Li, Ni Liu, Frances A. Shepherd, Teklab Gebregiworgis, Ming-Sound Tsao, Nadeem Moghal, Nhu-An Pham, Mitsuhiko Ikura, Ningdi Feng Liu, Zhenhao Fang, Hirotsugu Notsuda, Ku-Geng Huo, Christopher B. Marshall
Publikováno v:
Journal of Thoracic Oncology. 17:277-288
Introduction Mutations in BRAF occur in 2-4% of lung adenocarcinoma (LUAD) patients. Combination dabrafenib/trametinib or single-agent vemurafenib is approved only for patients with cancers driven by the V600E BRAF mutation. Targeted therapy is not c
Autor:
Francesca Ragusa, Alessandro Antonelli, Gilda Varricchi, Poupak Fallahi, Maria Rosaria Galdiero, Giusy Elia, Salvatore Benvenga, Silvia Martina Ferrari, Sabrina Rosaria Paparo
Publikováno v:
Seminars in Cancer Biology. 79:180-196
Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with medullary TC (MTC) and differentiated TC (DTC). In DTC patients, r